More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$289773419
EPS
-0.85
P/E ratio
--
Price to sales
1.25
Dividend yield
--
Beta
1.597673
Previous close
$5.27
Today's open
$5.23
Day's range
$4.37 - $5.36
52 week range
$1.17 - $5.44
show more
CEO
John T. Treace
Employees
450
Headquarters
Ponte Vedra, FL
Exchange
Nasdaq Global Select
Shares outstanding
65559597
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What Treace Medical Concepts (TMCI) Said on Its Q3 Earnings Call
Treace Medical Concepts NASDAQ: TMCI reported a 4% decline in third-quarter revenue as a shift toward lower-priced products and lower bunion procedure kit sales offset growth in procedure volumes. The company narrowed its full-year revenue outlook and said it expects to return to growth in the fourth quarter.
MarketBeat • Nov 6, 2026

Treace Medical Concepts, Inc. (TMCI) Q3 2026 Earnings Call Transcript
Treace Medical Concepts, Inc. ( TMCI ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Trip Taylor John Treace - Founder, Chairman & CEO Mark Hair - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Thank you for standing by, and welcome to Treace Medical Concepts Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Seeking Alpha • Nov 7, 2026

Treace Medical Concepts Reports Third Quarter 2026 Financial Results
PONTE VEDRA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, today reported financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 6, 2026

Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.26 per share a year ago.
Zacks Investment Research • Nov 6, 2026

Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor's Bunion Correction System
New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures
GlobeNewsWire • Nov 6, 2026

Treace to Present at the Stifel 2026 Healthcare Conference
PONTE VEDRA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced it will present at the Stifel 2026 Healthcare Conference, Wednesday, November 11, 2026, beginning at approximately 1:20 pm ET.
GlobeNewsWire • Nov 3, 2026

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2026 before the start of trading on Friday, November 6, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.
GlobeNewsWire • Oct 23, 2026

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire • Sep 26, 2026

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lapiplasty®, the MTA3D® Adductoplasty® and the SPRINT™ SpeedPlate® clinical studies.
GlobeNewsWire • Sep 17, 2026

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies
GlobeNewsWire • Sep 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Treace Medical Concepts Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.